Evidence map›Paper›PMID 24301059›Full record

ArticleEuropean journal of human genetics : EJHG2014

VHL mosaicism can be detected by clinical next-generation sequencing and is not restricted to patients with a mild phenotype.

Lucie Coppin, Claudine Grutzmacher, Michel Crépin, Evelyne Destailleur, Sophie Giraud, Catherine Cardot-Bauters, Nicole Porchet, Pascal Pigny

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Hemangioblastoma and mosaic von Hippel Lindau disease: rare presentation and review of the literature.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lucie Coppin1] Laboratoire de biochimie 'hormonologie, métabolisme-nutrition, oncologie', Centre de Biologie Pathologie, CHRU de Lille, Lille Cedex, France [2] INSERM, U837, Team 5, Lille Cedex, France.
Claudine GrutzmacherLaboratoire de biochimie 'hormonologie, métabolisme-nutrition, oncologie', Centre de Biologie Pathologie, CHRU de Lille, Lille Cedex, France.
Michel CrépinLaboratoire de biochimie 'hormonologie, métabolisme-nutrition, oncologie', Centre de Biologie Pathologie, CHRU de Lille, Lille Cedex, France.
Evelyne DestailleurLaboratoire de biochimie 'hormonologie, métabolisme-nutrition, oncologie', Centre de Biologie Pathologie, CHRU de Lille, Lille Cedex, France.
Sophie GiraudLaboratoire de génétique, Groupement Hospitalier Edouard Herriot, Lyon, France.
Catherine Cardot-BautersService d'endocrinologie et métabolismes, hôpital Claude-Huriez, CHRU de Lille, Lille Cedex, France.
Nicole Porchet1] Laboratoire de biochimie 'hormonologie, métabolisme-nutrition, oncologie', Centre de Biologie Pathologie, CHRU de Lille, Lille Cedex, France [2] INSERM, U837, Team 5, Lille Cedex, France.
Pascal Pigny1] Laboratoire de biochimie 'hormonologie, métabolisme-nutrition, oncologie', Centre de Biologie Pathologie, CHRU de Lille, Lille Cedex, France [2] INSERM, U837, Team 5, Lille Cedex, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of Von Hippel-Lindau (VHL) mosaic mutations by conventional Sanger sequencing requires a labour-intensive enrichment step, thus explaining that mosaicism occurrence is underestimated in patients. Nowadays, it is possible to detect mutation in cell sub-populations by next-generation sequencing (NGS). Here, we described a diagnosis strategy using NGS with high coverage in a series of eight patients who were negative for a VHL abnormality by Sanger sequencing and deletion search. In two patients, a mosaic mutation in VHL was detected by NGS. One patient with a 5.7% mutated allele frequency had a severe phenotype and an early disease onset. In conclusion, clinical NGS in an hospital molecular oncogenetics laboratory is an efficient tool to identify VHL mosaic mutation. Its use may improve patient monitoring and genetic counseling.

Indexed as

MosaicismPhenotypeAdolescentAdultFemaleGene FrequencyGenetic TestingHigh-Throughput Nucleotide SequencingHumansMaleMiddle Agedvon Hippel-Lindau DiseaseVon Hippel-Lindau Tumor Suppressor ProteinVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID24301059
PMCPMC4135403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.